Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio ™ for Refractory Chronic Cough

NEW HAVEN, Conn., Nov. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials